Carvedilol is a non-selective beta blocker with alpha-1 blocking activity indicated for heart failure, left ventricular dysfunction after myocardial infarction and hypertension. We supply it to US manufacturers of tablets and extended-release capsules.
Data from PubChem (CID 2585) and FDA’s substance registry
CAS number
72956-09-3
Molecular formula
C24H26N2O4
Molecular weight
406.5g/mol
FDA UNII
IUPAC name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
InChIKey
OGHNVEJMJSYVRP-UHFFFAOYSA-N
- Appearance
- White to off-white powder.
- Solubility
- Practically insoluble in water and gastric fluid. Freely soluble in dimethyl sulfoxide, soluble in methylene chloride and methanol, and sparingly soluble in ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
With so little solubility in water, particle size distribution is usually part of the specification. Carvedilol phosphate, used in extended-release capsules, is a separate API.
On the US market
- Reference product
- CoregNDA 020297
- Approved ANDAs
- 10 with a marketed product
- Approved forms and strengths
- Tablet 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com